Press Releases

  • Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

  • VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update

  • VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update

  • VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute

  • Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

  • Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

  • VolitionRx Limited Corrects an Earlier Announcement

  • VolitionRx Limited to Present at Multiple Investor Conferences in June

  • A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

  • VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus